Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/10785
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nicholaou, Theo | en |
dc.contributor.author | Ebert, Lisa M | en |
dc.contributor.author | Davis, Ian D | en |
dc.contributor.author | McArthur, Grant A | en |
dc.contributor.author | Jackson, Heather M | en |
dc.contributor.author | Dimopoulos, Nektaria | en |
dc.contributor.author | Tan, Bee | en |
dc.contributor.author | Maraskovsky, Eugene | en |
dc.contributor.author | Miloradovic, Lena | en |
dc.contributor.author | Hopkins, Wendie | en |
dc.contributor.author | Pan, Linda | en |
dc.contributor.author | Venhaus, Ralph | en |
dc.contributor.author | Hoffman, Eric W | en |
dc.contributor.author | Chen, Weisan | en |
dc.contributor.author | Cebon, Jonathan S | en |
dc.date.accessioned | 2015-05-16T00:21:00Z | |
dc.date.available | 2015-05-16T00:21:00Z | |
dc.date.issued | 2009-03-10 | en |
dc.identifier.citation | Clinical Cancer Research 2009; 15(6): 2166-73 | en |
dc.identifier.govdoc | 19276262 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/10785 | en |
dc.description.abstract | NY-ESO-1 is a highly immunogenic antigen expressed in a variety of malignancies, making it an excellent target for cancer vaccination. We recently developed a vaccine consisting of full-length recombinant NY-ESO-1 protein formulated with ISCOMATRIX adjuvant, which generated strong humoral and T-cell-mediated immune responses and seemed to reduce the risk of disease relapse in patients with fully resected melanoma. This study examines the clinical and immunologic efficacy of the same vaccine in patients with advanced metastatic melanoma.Delayed-type hypersensitivity responses, circulating NY-ESO-1-specific CD4(+) and CD8(+) T cells, and proportions of regulatory T cells (Treg) were assessed in patients.In contrast to patients with minimal residual disease, advanced melanoma patients showed no clinical responses to vaccination. Although strong antibody responses were mounted, the generation of delayed-type hypersensitivity responses was significantly impaired. The proportion of patients with circulating NY-ESO-1-specific CD4(+) T cells was also reduced, and although many patients had CD8(+) T cells specific to a broad range of NY-ESO-1 epitopes, the majority of these responses were preexisting. Tregs were enumerated in the blood by flow cytometric detection of cells with a CD4(+)CD25(+)FoxP3(+) and CD4(+)CD25(+)CD127(-) phenotype. Patients with advanced melanoma had a significantly higher proportion of circulating Treg compared with those with minimal residual disease.Our results point to a tumor-induced systemic immune suppression, showing a clear association between the stage of melanoma progression, the number of Treg in the blood, and the clinical and immunologic efficacy of the NY-ESO-1 ISCOMATRIX cancer vaccine. | en |
dc.language.iso | en | en |
dc.subject.other | Adjuvants, Immunologic.administration & dosage | en |
dc.subject.other | Adult | en |
dc.subject.other | Aged | en |
dc.subject.other | Aged, 80 and over | en |
dc.subject.other | Antigens, Neoplasm.administration & dosage.immunology | en |
dc.subject.other | Cancer Vaccines.administration & dosage.immunology | en |
dc.subject.other | Cholesterol.administration & dosage | en |
dc.subject.other | Drug Combinations | en |
dc.subject.other | Female | en |
dc.subject.other | Humans | en |
dc.subject.other | Hypersensitivity, Delayed.etiology | en |
dc.subject.other | Male | en |
dc.subject.other | Melanoma.therapy | en |
dc.subject.other | Membrane Proteins.administration & dosage.immunology | en |
dc.subject.other | Middle Aged | en |
dc.subject.other | Phospholipids.administration & dosage | en |
dc.subject.other | Saponins.administration & dosage | en |
dc.subject.other | T-Lymphocytes.immunology | en |
dc.subject.other | T-Lymphocytes, Regulatory.physiology | en |
dc.subject.other | Vaccination | en |
dc.title | Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Clinical Cancer Research | en |
dc.identifier.affiliation | Ludwig Institute for Cancer Research, Austin Health, Peter MacCallum Cancer Centre, CSL Limited, Melbourne, Victoria, Australia | en |
dc.identifier.doi | 10.1158/1078-0432.CCR-08-2484 | en |
dc.description.pages | 2166-73 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/19276262 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Cebon, Jonathan S | |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.